Do analysts recommend BCTX or FTLF?

FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 115.84%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts plainly believe FitLife Brands is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to BCTX or FTLF?

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Briacell Therap's score of 0.47 indicating that FitLife Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer ETHZ or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ETHZ or BCTX more profitable?

Briacell Therap's return on equity of -173.08% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Flag Ship Acquisition N/A -185.71% -83.12% Briacell Therap N/A -173.08% -139.64%

Do analysts rate ICCC or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ICCC or BCTX more profitable?

Briacell Therap has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Briacell Therap N/A -173.08% -139.64%

Do analysts rate BCTX or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BCTX or THAR?

Tharimmune is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$23.33 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is BCTX or THAR more profitable?

Briacell Therap's return on equity of -173.08% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -173.08% -139.64% Tharimmune N/A -588.45% -264.41%

Do analysts recommend BCTX or PMN?

Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 166.57%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable earnings and valuation, BCTX or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$23.33 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is BCTX or PMN more profitable?

Briacell Therap's return on equity of -173.08% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -173.08% -139.64% Promis Neurosciences N/A -237.99% -151.04%

Does the media favor BCTX or PMN?

In the previous week, Briacell Therap had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Briacell Therap and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.47 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Briacell Therap (BCTX) Competitors

$3.26 -0.05 (-1.36%)

As of 03:27 PM Eastern

Compare

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

Should you buy Briacell Therap stock or one of its competitors? MarketBeat compares Briacell Therap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Briacell Therap include FitLife Brands (FTLF), Flag Ship Acquisition (ETHZ), ImmuCell (ICCC), Tharimmune (THAR), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Briacell Therap compare to FitLife Brands?

Briacell Therap (NASDAQ:BCTX) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 61.4% of FitLife Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Briacell Therap's score of 0.47 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 115.84%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts plainly believe FitLife Brands is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

FitLife Brands has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
FitLife Brands	$81.46M	1.15	$6.33M	$0.60	16.60

FitLife Brands has a net margin of 6.64% compared to Briacell Therap's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
FitLife Brands	6.64%	18.31%	8.21%

Summary

FitLife Brands beats Briacell Therap on 12 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and Briacell Therap (NASDAQ:BCTX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Briacell Therap had 3 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for Flag Ship Acquisition. Briacell Therap's average media sentiment score of 0.47 beat Flag Ship Acquisition's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Overall Sentiment
Flag Ship Acquisition	Neutral
Briacell Therap	Neutral

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap's return on equity of -173.08% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
Briacell Therap	N/A	-173.08%	-139.64%

Flag Ship Acquisition has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	22.53	-$6.17M	-$159.65	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Summary

Briacell Therap beats Flag Ship Acquisition on 6 of the 11 factors compared between the two stocks.

How does Briacell Therap compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

ImmuCell has higher revenue and earnings than Briacell Therap. ImmuCell is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$29.93M	2.98	-$1.04M	-$0.06	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmuCell has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

In the previous week, Briacell Therap had 3 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.89 beat Briacell Therap's score of 0.47 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Very Positive
Briacell Therap	Neutral

Briacell Therap has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Briacell Therap	N/A	-173.08%	-139.64%

Summary

ImmuCell beats Briacell Therap on 7 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to Tharimmune?

Briacell Therap (NASDAQ:BCTX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Briacell Therap had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for Tharimmune. Briacell Therap's average media sentiment score of 0.47 beat Tharimmune's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Neutral
Tharimmune	Neutral

Briacell Therap's return on equity of -173.08% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Tharimmune	N/A	-588.45%	-264.41%

Tharimmune is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Briacell Therap beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Briacell Therap compare to Promis Neurosciences?

Briacell Therap (NASDAQ:BCTX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Briacell Therap had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Briacell Therap and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.47 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 166.57%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Briacell Therap's return on equity of -173.08% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Promis Neurosciences	N/A	-237.99%	-151.04%

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Summary

Promis Neurosciences beats Briacell Therap on 8 of the 14 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.66M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.14	18.86	23.86	24.42
Price / Sales	N/A	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.35	6.81	10.04	6.74
Net Income	-$26.31M	$24.09M	$3.56B	$337.03M
7 Day Performance	-8.80%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-90.08%	48.97%	28.80%	34.36%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.578 of 5 stars	$3.27 -1.4%	N/A	-90.2%	$23.66M	N/A	N/A	8
FTLF FitLife Brands	4.5516 of 5 stars	$9.91 +2.0%	$21.50 +117.0%	-30.3%	$93.06M	$81.46M	16.41	20
ETHZ Flag Ship Acquisition	N/A	$4.77 +4.4%	N/A	N/A	$90.69M	$4.11M	N/A	7
ICCC ImmuCell	0.9377 of 5 stars	$9.91 +1.2%	N/A	+46.3%	$89.69M	$27.64M	N/A	70	Positive News Short Interest Decrease
THAR Tharimmune	N/A	$2.37 -15.5%	N/A	+51.4%	$89.42M	N/A	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

How does Briacell Therap compare to FitLife Brands?

Summary

How does Briacell Therap compare to Flag Ship Acquisition?

Summary

How does Briacell Therap compare to ImmuCell?

Summary

How does Briacell Therap compare to Tharimmune?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

How does Briacell Therap compare to FitLife Brands?

Do insiders & institutionals have more ownership in BCTX or FTLF?

Does the media refer more to BCTX or FTLF?

Do analysts recommend BCTX or FTLF?

Which has more volatility and risk, BCTX or FTLF?

Which has preferable earnings & valuation, BCTX or FTLF?

Is BCTX or FTLF more profitable?

Summary

How does Briacell Therap compare to Flag Ship Acquisition?

Does the media refer more to ETHZ or BCTX?

Do institutionals & insiders hold more shares of ETHZ or BCTX?

Which has more risk and volatility, ETHZ or BCTX?

Do analysts prefer ETHZ or BCTX?

Is ETHZ or BCTX more profitable?

Which has preferable earnings and valuation, ETHZ or BCTX?

Summary

How does Briacell Therap compare to ImmuCell?

Which has preferable earnings and valuation, ICCC or BCTX?

Do analysts rate ICCC or BCTX?

Do insiders & institutionals believe in ICCC or BCTX?

Which has more risk and volatility, ICCC or BCTX?

Does the media favor ICCC or BCTX?

Is ICCC or BCTX more profitable?

Summary

How does Briacell Therap compare to Tharimmune?

Do insiders & institutionals hold more shares of BCTX or THAR?

Does the media favor BCTX or THAR?

Is BCTX or THAR more profitable?

Which has stronger earnings and valuation, BCTX or THAR?

Which has more risk and volatility, BCTX or THAR?

Do analysts rate BCTX or THAR?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Do institutionals & insiders hold more shares of BCTX or PMN?

Does the media favor BCTX or PMN?

Which has more risk & volatility, BCTX or PMN?

Do analysts recommend BCTX or PMN?

Is BCTX or PMN more profitable?

Which has preferable earnings and valuation, BCTX or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools